Filing Details

Accession Number:
0001181431-12-067220
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-12-27 10:28:46
Reporting Period:
2012-12-24
Filing Date:
2012-12-27
Accepted Time:
2012-12-27 10:28:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1365216 Sucampo Pharmaceuticals Inc. SCMP Pharmaceutical Preparations (2834) 133929237
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1384370 Ryuji Ueno 4520 East-West Highway
Suite 300
Bethesda MD 20814
Ceo, Chief Scientific Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2012-12-24 15,916 $5.01 26,154,993 No 4 S Indirect By S&R Technology Holdings, LLC
Class A Common Stock Disposition 2012-12-26 4,346 $5.00 26,150,647 No 4 S Indirect By S&R Technology Holdings, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By S&R Technology Holdings, LLC
No 4 S Indirect By S&R Technology Holdings, LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 148,530 Direct
Class A Common Stock 60,357 Indirect By Wife
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on August 29, 2012.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. S&R Technology Holdings, LLC is wholly owned by Dr. Ueno and his wife. Dr. Ueno disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.01, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. Dr. Ueno disclaims beneficial ownership of the reported securities.